Maurits Wondergem1, Friso M van der Zant2, Peter W Vlottes3, Remco J J Knol2. 1. Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands; and m.wondergem@nwz.nl. 2. Department of Nuclear Medicine, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands; and. 3. Radiopharmacy, Noordwest Ziekenhuisgroep, Alkmaar, The Netherlands.
Abstract
In the literature, a 4- to 6-h fast is recommended before a patient undergoes PET/CT with 2-(3-(1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18F-DCFPyL); however, a scientific underpinning for this recommendation is lacking. Therefore, we performed a study to determine the impact of fasting on 18F-DCFPyL uptake. Methods: The study included 50 patients who fasted at least 6 h before 18F-DCFPyL administration and 50 patients who did not. Activity (SUVmax) was measured in lesions characteristic of prostate cancer and in normal tissues known to express high physiologic uptake. Results: Uptake in suspected lesions did not differ between the cohorts. 18F-DCFPyL uptake in the submandibular gland, liver, and spleen was significantly higher in the fasting than the nonfasting cohort. Conclusion: Our data show that fasting does not significantly affect 18F-DCFPyL uptake in suspected malignant lesions but does result in significantly lower 18F-DCFPyL uptake in tissues with high physiologic uptake. The absolute differences in uptake were relatively small; therefore, the effects of fasting on the diagnostic performance can be considered negligible.
In the literature, a 4- to 6-h fast is recommended before a patient undergoes PET/CT with 2-(3-(1-carboxy-5-[(6-18F-fluoro-pyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid (18F-DCFPyL); however, a scientific underpinning for this recommendation is lacking. Therefore, we performed a study to determine the impact of fasting on 18F-DCFPyL uptake. Methods: The study included 50 patients who fasted at least 6 h before 18F-DCFPyL administration and 50 patients who did not. Activity (SUVmax) was measured in lesions characteristic of prostate cancer and in normal tissues known to express high physiologic uptake. Results: Uptake in suspected lesions did not differ between the cohorts. 18F-DCFPyL uptake in the submandibular gland, liver, and spleen was significantly higher in the fasting than the nonfasting cohort. Conclusion: Our data show that fasting does not significantly affect 18F-DCFPyL uptake in suspected malignant lesions but does result in significantly lower 18F-DCFPyL uptake in tissues with high physiologic uptake. The absolute differences in uptake were relatively small; therefore, the effects of fasting on the diagnostic performance can be considered negligible.
Authors: Karine Sahakyan; Xin Li; Martin A Lodge; Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Harshad R Kulkarni; Christiane Schuchardt; Richard P Baum; Kenneth J Pienta; Martin G Pomper; Ashley E Ross; Michael A Gorin; Steven P Rowe Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe; Martin A Lodge; Ralph A Bundschuh Journal: Mol Imaging Biol Date: 2020-02 Impact factor: 3.488
Authors: Etienne Rousseau; Don Wilson; Frédéric Lacroix-Poisson; Andra Krauze; Kim Chi; Martin Gleave; Michael McKenzie; Scott Tyldesley; S Larry Goldenberg; François Bénard Journal: J Nucl Med Date: 2019-04-12 Impact factor: 10.057